Insulin resistance and the effects of thiazolidinediones on cardiac metabolism

American Journal of Medicine

Volumn 115, Issue 8 SUPPL. 1, 2003, Pages 75-80

  Young, Lawrence H ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; FATTY ACID; GLUCOSE; LACTIC ACID;

CLINICAL TRIAL; CONFERENCE PAPER; DISEASE ASSOCIATION; ENERGY METABOLISM; ENERGY TRANSFER; GLUCOSE METABOLISM; HEART CONTRACTION; HEART MUSCLE METABOLISM; HUMAN; INSULIN RESISTANCE; MYOCARDIAL DISEASE; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL;

EID: 0346219293     PISSN: 00029343     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjmed.2003.09.013     Document Type: Conference Paper

References (60)

1. Opie L. The Heart: Physiology and Metabolism. 1991;Raven Press, New York.
2. Young L.H., Russel R.R., Chyun D., Ramahi T. Heart failure in diabetic patients. Johnstone M.T., Veves A. Diabetes and Cardiovascular Disease. 2001;281-298 Humana Press, Totowa, NJ.
3. Stanley W.C., Lopaschuk G.D., McCormack J.G. Regulation of energy substrate metabolism in the diabetic heart. Cardiovasc Res. 34:1997;25-33.
4. Taegtmeyer H., McNulty P., Young M.E. Adaptation and maladaptation of the heart in diabetes, part I general concepts . Circulation. 105:2002;1727-1733.
5. Young M.E., McNulty P., Taegtmeyer H. Adaptation and maladaptation of the heart in diabetes, part II potential mechanisms . Circulation. 105:2002;1861-1870.
6. Apstein C.S., Taegtmeyer H. Glucose-insulin-potassium in acute myocardial infarction the time has come for a large, prospective trial . Circulation. 96:1997;1074-1077.
7. Lopaschuk G.D., Rebeyka I.M., Allard M.F. Metabolic modulation a means to mend a broken heart . Circulation. 105:2002;140-142.
8. Lewandowski E.D. Metabolic mechanisms associated with antianginal therapy. Circ Res. 86:2000;487-489.
9. Young L.H., Russell R.R. III, Yin R., et al. Regulation of myocardial glucose uptake and transport during ischemia and energetic stress. Am J Cardiol. 83:1999;25H-30H.
10. Young L.H., Coven D.L., Russell R.R. III. Cellular and molecular regulation of cardiac glucose transport. J Nucl Cardiol. 7:2000;267-276.
11. Young L.H., Renfu Y., Russell R.R., et al. Low-flow ischemia leads to translocation of canine heart GLUT-4 and GLUT-1 glucose transporters to the sarcolemma in vivo. Circulation. 95:1997;415-422.
12. Hofmann C., Lorenz K., Colca J.R. Glucose transport deficiency in diabetic animals is corrected by treatment with the oral antihyperglycemic agent pioglitazone. Endocrinology. 129:1991;1915-1925.
13. Hirshman M.F., Fagnant P.M., Horton E.D., et al. Pioglitazone treatment for 7 days failed to correct the defect in glucose transport and glucose transporter translocation in obese Zucker rat (fa/fa) skeletal muscle plasma membranes. Biochem Biophys Res Commun. 208:1995;835-845.
14. Kramer D., Shapiro R., Adler A., et al. Insulin-sensitizing effect of rosiglitazone (BRL-49653) by regulation of glucose transporters in muscle and fat of Zucker rats. Metabolism. 50:2001;1294-1300.
15. Bähr M., Spelleken M., Bock M., et al. Acute and chronic effects of troglitazone (CS-045) on isolated rat ventricular cardiomyocytes. Diabetologia. 39:1996;766-774.
16. Sidell R.J., Cole M.A., Draper N.J., et al. Thiazolidinedione treatment normalizes insulin resistance and ischemic injury in the Zucker fatty rat heart. Diabetes. 51:2002;1110-1117.
17. Khandoudi N., Delerive P., Berrebi-Bertrand I., et al. Rosiglitazone, a peroxisome proliferator-activated receptor-gamma, inhibits the Jun NH2-terminal kinase/activating protein 1 pathway and protects the heart from ischemia/reperfusion injury. Diabetes. 51:2002;1507-1514.
18. Kainulainen H., Breiner M., Schürmann A., et al. In vivo glucose uptake and glucose transporter proteins GLUT1 and GLUT4 in heart and various types of skeletal muscle from streptozotocin-diabetic rats. Biochim Biophys Acta. 1225:1994;275-282.
19. Hall J., Sexton W.L., Stanley W.C. Exercise training attenuates the reduction in myocardial GLUT-4 in diabetic rats. J Appl Physiol. 78:1995;76-81.
20. Voipio-Pulkki L.-M., Nuutila P., Knuuti M.J., et al. Heart and skeletal muscle glucose disposal in type 2 diabetic patients as determined by positron emission tomography. J Nucl Med. 34:1993;2064-2067.
21. Ohtake T., Yokoyama I., Watanabe T., et al. Myocardial glucose metabolism in noninsulin-dependent diabetes mellitus patients evaluated by FDG-PET. J Nucl Med. 36:1995;456-463.
22. Utriainen T., Takala T., Luotolahti M., et al. Insulin resistance characterizes glucose uptake in skeletal muscle but not in the heart in NIDDM. Diabetologia. 41:1998;555-559.
23. Mäki M., Nuutila P., Laine H., et al. Myocardial glucose uptake in patients with NIDDM and stable coronary artery disease. Diabetes. 46:1997;1491-1496.
24. Slot J.W., Geuze H.J., Gigengack S., et al. Translocation of the glucose transporter GLUT4 in cardiac myocytes of the rat. Proc Natl Acad Sci U S A. 88:1991;7815-7819.
25. Griffin M.E., Marcucci M.J., Cline G.W., et al. Free fatty acid-induced insulin resistance is associated with activation of protein kinase C θ and alterations in the insulin signaling cascade. Diabetes. 48:1999;1270-1274.
26. Yu C., Chen Y., Cline G.W., et al. Mechanism by which fatty acids inhibit insulin activation of insulin receptor substrate-1 (IRS-1)-associated phosphatidylinositol 3-kinase activity in muscle. J Biol Chem. 277:2002;50230-50236.
27. Jucker B.M., Schaeffer T.R., Haimbach R.E., et al. Normalization of skeletal muscle glycogen synthesis and glycolysis in rosiglitazone-treated Zucker fatty rats an in vivo nuclear magnetic resonance study . Diabetes. 51:2002;2066-2073.
28. Shintani M., Nishimura H., Yonemitsu S., et al. Troglitazone not only increases GLUT4 but also induces its translocation in rat adipocytes. Diabetes. 50:2001;2296-2300.
29. Yonemitsu S., Nishimura H., Shintani M., et al. Troglitazone induces GLUT4 translocation in L6 myotubes. Diabetes. 50:2001;1093-1101.
30. Brunmair B., Gras F., Neschen S., et al. Direct thiazolidinedione action on isolated rat skeletal muscle fuel handling is independent of peroxisome proliferator-activated receptor-gamma-mediated changes in gene expression. Diabetes. 50:2001;2309-2315.
31. Winder W.W., Hardie D.G. AMP-activated protein kinase, a metabolic master switch possible roles in type 2 diabetes . Am J Physiol. 277:1999;E1-E10.
32. Hardie D.G., Carling D. The AMP-activated protein kinase fuel gauge of the mammalian cell? Eur J Biochem. 246:1997;259-273.
33. Russell R.R. III, Bergeron R., Shulman G.I., Young L.H. Translocation of myocardial GLUT-4 and increased glucose uptake through activation of AMPK by AICAR. Am J Physiol. 277:1999;H643-H649.
34. Bergeron R., Russell R.R. III, Young L.H., et al. Effect of AMPK activation on muscle glucose metabolism in conscious rats. Am J Physiol. 276:1999;E938-E944.
35. Fryer L.G.D., Parbu-Patel A., Carling D. The anti-diabetic drugs rosiglitazone and metformin stimulate AMP-activated protein kinase through distinct signaling pathways. J Biol Chem. 277:2002;25226-25232.
36. Kudo N., Gillespie J.G., Kung L., et al. Characterization of 5'AMP-activated protein kinase activity in the heart and its role in inhibiting acetyl-CoA carboxylase during reperfusion following ischemia. Biochim Biophys Acta. 1301:1996;67-75.
37. Bergeron R., Ren J.M., Cadman K.S., et al. Chronic activation of AMP kinase results in NRF-1 activation and mitochondrial biogenesis. Am J Physiol. 281:2001;E1340-E1346.
38. Sandouk T., Reda D., Hofmann C. The antidiabetic agent pioglitazone increases expression of glucose transporters in 3T3-F442A cells by increasing messenger ribonucleic acid transcript stability. Endocrinology. 133:1993;352-359.
39. Kramer D., Shapiro R., Adler A., Bush E., Rondinone C.M. Insulin-sensitizing effect of rosiglitazone (BRL-49653) by regulation of glucose transporters in muscle and fat of Zucker rats. Metabolism. 50:2001;1294-1300.
40. Taegtmeyer H., King L.M., Jones B.E. Energy substrate metabolism, myocardial ischemia, and targets for pharmacotherapy. Am J Cardiol. 82:1998;54K-60K.
41. Longnus S.L., Wambolt R.B., Barr R.L., et al. Regulation of myocardial fatty acid oxidation by substrate supply. Am J Physiol. 281:2001;H1561-H1567.
42. Lopaschuk G.D., Tsang H. Metabolism of palmitate in isolated working hearts from spontaneously diabetic 'BB' Wistar rats. Circ Res. 61:1987;853-858.
43. Zhou Y.-T., Grayburn P., Karim A., et al. Lipotoxic heart disease in obese rats implications for human obesity . Proc Natl Acad Sci U S A. 97:2000;1784-1789.
44. Unger R.H., Orci L. Diseases of liporegulation new perspectives on obesity and related disorders . FASEB J. 15:2001;312-321.
45. Glatz J.F., Storch J. Unravelling the significance of cellular fatty acid-binding proteins. Curr Opin Lipidol. 12:2001;267-274.
46. Luiken J.J.F.P., Arumugam Y., Dyck D.J., et al. Increased rates of fatty acid uptake and plasmalemmal fatty acid transporters in obese Zucker rats. J Biol Chem. 276:2001;40567-40573.
47. Luiken J.J., Arumugam Y., Bell R.C., et al. Changes in fatty acid transport and transporters are related to the severity of insulin deficiency. Am J Physiol. 283:2002;E612-E621.
48. Ruderman N.B., Saha A.K., Vavvas D., Witters L.A. Malonyl-CoA, fuel sensing, and insulin resistance. Am J Physiol. 276:1999;E1-E18.
49. Saha A.K., Schwarsin A.J., Roduit R., et al. Activation of malonyl-CoA decarboxylase in rat skeletal muscle by contraction and the AMP-activated protein kinase activator 5-aminoimidazole-4-carboxamide-1-beta-D-ribofuranoside. J Biol Chem. 275:2000;24279-24283.
50. McMaster University Health Sciences. McMaster research team awarded $25 million for diabetes clinical trial. November 1, 2000. Available at: http://www.fhs.mcmaster.ca/pubrel/dream.htm. Accessed January 28, 2003.
51. University of Pittsburgh Epidemiology Data Center. BARI 2D: a vital study for treating type 2 diabetes and coronary artery disease. 2002. Available at: http://www.bari2d.org/index.html. Accessed December 18, 2002.
52. Viberti G., Kahn S.E., Greene D.A., et al. A Diabetes Outcome Progression Trial (ADOPT) an international multicenter study of the comparative efficacy of rosiglitazone, glyburide, and metformin in recently diagnosed type 2 diabetes . Diabetes Care. 25:2002;1737-1743.
53. Zhu P., Lu L., Xu Y., Schwartz G.G. Troglitazone improves recovery of left ventricular function after regional ischemia in pigs. Circulation. 101:2000;1165-1171.
54. Shimabukuro M., Higa S., Shinzato T., et al. Cardioprotective effects of troglitazone in streptozotocin-induced diabetic rats. Metabolism. 45:1996;1168-1173.
55. Yue T., Chen J., Bao W., et al. In vivo myocardial protection from ischemia/reperfusion injury by the peroxisome proliferator-activated receptor-γ agonist rosiglitazone. Circulation. 104:2001;2588-2594.
56. Liao R., Jain M., Cui L., et al. Cardiac-specific overexpression of GLUT1 prevents the development of heart failure attributable to pressure overload in mice. Circulation. 106:2002;2125-2131.
57. Raji A., Seely E.W., Bekins S.A., et al. Rosiglitazone improves insulin sensitivity and lowers blood pressure in hypertensive patients. Diabetes Care. 26:2003;172-178.
58. St. John Sutton M., Rendell M., Dandona P., et al. A comparison of the effects of rosiglitazone and glyburide on cardiovascular function and glycemic control in patients with type 2 diabetes. Diabetes Care. 25:2002;2058-2064.
59. Asakawa M., Takano H., Nagai T., et al. Peroxisome prolif-erator- activated receptor γ plays a critical role in inhibition of cardiac hypertrophy in vitro and in vivo. Circulation. 105:2002;1240-1246.
60. Young L.H., Chyun D. Heart disease in patients with diabetes. Porte D. Jr, Baron A., Sherwin R. Ellenberg & Rifkin's Diabetes Mellitus. 2002;823-844 McGraw-Hill, New York.